To Top

Anti Infective


Anti-Infective is a Therapy Area (TA) that covers over 16% revenue of the total Indian Pharmaceutical Market (IPM).

Alkem holds the apex rank in anti-infective TA with a wide range of medicines that fight against different kinds of infections.

Alkem has expertise in a wide range of formulations that include tablets, dry syrups and sterile dosage forms. Alkem controls 11%* of the total anti-infective Therapy Area (TA) of the Indian Pharmaceutical Market (IPM).

From the outset, brand building has been the greatest strength of Alkem. This has helped us become the only company with 8 anti-infective brands featuring amongst the top 300 brands of Indian Pharmaceutical Market. This has played a key role in propelling Alkem to the summit of anti-infective TA.

Some of the highlights of Alkem’s Anti-infective portfolio are

  • CLAVAM, TAXIM-O, TAXIM, PIPZO, SWICH, XONE, XONE-XP & ZOCEF, the pillar brands of Alkem in anti-infective are the key contributors to Indian Pharmaceutical Market.
  • Alkem is the pioneer to launch Arbekacin in India. Arbekacin is a novel semisynthetic aminoglycoside antibiotic, marketed in Japan and Korea since 1990 and have been treated globally.

* MAT May 2019